Identification of a novel form of caspase-independent cell death triggered by BH3-mimetics in diffuse large B-cell lymphoma cell lines

Cell Death Dis. 2024 Apr 15;15(4):266. doi: 10.1038/s41419-024-06652-3.

Abstract

BH3-mimetics represent promising anti-cancer agents in tumors that rely on the anti-apoptotic function of B-Cell Lymphoma 2 (BCL2) proteins, particularly in leukemia and lymphoma cells primed for apoptosis. Mechanistically, BH3-mimetics may displace pro-apoptotic binding partners thus inducing BAX/BAK-mediated mitochondrial permeabilization followed by cytochrome c release, activation of the caspase cascade and apoptosis. Here, we describe a novel mode of caspase-independent cell death (CICD) induced by BH3-mimetics in a subset of diffuse large B-cell lymphoma (DLBCL) cells. Of note, rather than occurring via necroptosis, CICD induced immediately after mitochondrial permeabilization was associated with transcriptional reprogramming mediated by activation of c-Jun N-terminal Kinase (JNK) signaling and Activator Protein 1 (AP1). Thereby, CICD resulted in the JNK/AP1-mediated upregulation of inflammatory chemokines and increased migration of cytotoxic Natural Killer (NK) cells. Taken together, our study describes a novel mode of CICD triggered by BH3-mimetics that may alter the immune response towards dying cells.

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Apoptosis
  • Caspases
  • Cell Line
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • bcl-2 Homologous Antagonist-Killer Protein / metabolism
  • bcl-2-Associated X Protein / metabolism

Substances

  • bcl-2-Associated X Protein
  • bcl-2 Homologous Antagonist-Killer Protein
  • Antineoplastic Agents
  • Caspases
  • Proto-Oncogene Proteins c-bcl-2